Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Drynaria rhizome extract is a herbal preparation derived from the rhizomes of *Drynaria fortunei*, a fern widely used in Traditional Chinese Medicine (TCM) for bone-related conditions such as osteoporosis and fractures. Recent research indicates its potential in managing metabolic disorders. It functions by activating the adenosine monophosphate-activated protein kinase (AMPK) pathway, which in turn downregulates lipogenic transcription factors like sterol regulatory element-binding protein-1 (SREBP-1) and peroxisome proliferator-activated receptor-gamma (PPAR-γ). This mechanism leads to reduced lipid accumulation in the liver and adipose tissue, suggesting a dual role in bone health and obesity management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on drynaria rhizome extract.